Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective.

SW, Quist; Loon J, van; S, Bakker; M, Pochopién; MJ, Postma; J, Paulissen

doi:10.1136/bmjph-2024-001288

Public

Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective.

Published in BMJ public health • Jun 25, 2025

Authors:

Quist SW

van Loon J

Bakker S

Abstract

Abstract Introduction One in three patients with type 2 diabetes (T2D) suffers from any stage of chronic kidney disease (CKD), a chronic illness associated with a high global burden that impacts not only the healthcare system but also societal costs. Addition of finerenone to the standard of care (S...

Subject

Cardiovascular diseases

Economics

Public Health

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!